2021 05 17 - Manufacturer´s authorization for tTF-NGR renewed

2021 11 12 - Start of phase III study (TRABTRAP) in patients with soft tissue sarcomas (dose-finding cohort, phase I/II)   
 
2025 03 07 - Start of the main phase III part of TRABTRAP randomizing trabectedin standard of care versus trabectedin plus tTF-NGR

2025 10 21 - Publication of the results of the safety cohort of TRABTRAP at ESMO 2025, Berlin

2026 02 19 - Publication of the results of the safety cohort of TRABTRAP in the peer-reviewed journal Scientific Reports (Nature Portfolio journal)